Juan Fu

4.9k total citations · 2 hit papers
42 papers, 3.4k citations indexed

About

Juan Fu is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Juan Fu has authored 42 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Immunology, 20 papers in Oncology and 16 papers in Molecular Biology. Recurrent topics in Juan Fu's work include Cancer Immunotherapy and Biomarkers (10 papers), Immunotherapy and Immune Responses (8 papers) and Immune Cell Function and Interaction (7 papers). Juan Fu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Immunotherapy and Immune Responses (8 papers) and Immune Cell Function and Interaction (7 papers). Juan Fu collaborates with scholars based in United States, China and Japan. Juan Fu's co-authors include Drew M. Pardoll, Fan Pan, Gregg L. Semenza, Hong Yu, Larissa A. Shimoda, Suzanne L. Topalian, Huang‐Yu Yang, Weibo Luo, Hung‐Rong Yen and Chi V. Dang and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Juan Fu

41 papers receiving 3.4k citations

Hit Papers

Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1 2011 2026 2016 2021 2011 2015 400 800 1.2k

Peers

Juan Fu
Noelyn M. Kljavin United States
Jianxun Song United States
Andrew L. Doedens United States
Luca Cassetta United Kingdom
Juan Fu
Citations per year, relative to Juan Fu Juan Fu (= 1×) peers Asís Palazón

Countries citing papers authored by Juan Fu

Since Specialization
Citations

This map shows the geographic impact of Juan Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juan Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juan Fu more than expected).

Fields of papers citing papers by Juan Fu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juan Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juan Fu. The network helps show where Juan Fu may publish in the future.

Co-authorship network of co-authors of Juan Fu

This figure shows the co-authorship network connecting the top 25 collaborators of Juan Fu. A scholar is included among the top collaborators of Juan Fu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juan Fu. Juan Fu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Sophia Y., Heng‐Chung Kung, Kai Chen, et al.. (2025). Distinct response to IL-1β blockade in liver- and lung-specific metastasis mouse models of pancreatic cancer with heterogeneous tumor microenvironments. Experimental Hematology and Oncology. 14(1). 13–13. 1 indexed citations
2.
Sun, Wei‐Chih, Juan Fu, Keyu Li, et al.. (2024). Semaphorin 3D promotes pancreatic ductal adenocarcinoma progression and metastasis through macrophage reprogramming. Science Advances. 10(42). eadp0684–eadp0684. 6 indexed citations
3.
Chen, Sophia Y., Heng‐Chung Kung, Kai Chen, et al.. (2024). Targeting heterogeneous tumor microenvironments in pancreatic cancer mouse models of metastasis by TGF-β depletion. JCI Insight. 9(21). 6 indexed citations
4.
Liu, Yongping, et al.. (2024). Global, regional, and national burden of acute lymphoblastic leukemia in children: Epidemiological trends analysis from 1990 to 2021. iScience. 27(12). 111356–111356. 8 indexed citations
6.
Wei, Ping, Wei Kou, Farooq Riaz, et al.. (2023). Combination therapy of HIFα inhibitors and Treg depletion strengthen the anti‐tumor immunity in mice. European Journal of Immunology. 53(12). e2250182–e2250182. 3 indexed citations
7.
Chen, Sophia Y., Heng‐Chung Kung, Rui Zhang, et al.. (2023). Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC. Cancer Letters. 573. 216366–216366. 7 indexed citations
8.
Taylor, David, Rupashree Sen, Juan Fu, et al.. (2022). MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses. Frontiers in Immunology. 13. 936129–936129. 3 indexed citations
9.
Fu, Juan, Ya-Wen Fu, Zhi-Xue Yang, et al.. (2022). Improved and Flexible HDR Editing by Targeting Introns in iPSCs. Stem Cell Reviews and Reports. 18(5). 1822–1833. 8 indexed citations
10.
Shaikh, Fyza Y., Joell J. Gills, Fuad Mohammad, et al.. (2022). Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors. Cancer Immunology Immunotherapy. 71(10). 2405–2420. 22 indexed citations
11.
Zhang, Qian, Guoping Liu, Ji‐Bin Liu, et al.. (2021). The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice. Molecular Therapy — Oncolytics. 20. 556–568. 49 indexed citations
12.
Yin, Han, et al.. (2019). Aggregate analysis based on TCGA: TTN missense mutation correlates with favorable prognosis in lung squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology. 145(4). 1027–1035. 49 indexed citations
13.
Zeng, Qi, Juan Fu, Michael Korrer, et al.. (2018). Caspase-1 from Human Myeloid-Derived Suppressor Cells Can Promote T Cell–Independent Tumor Proliferation. Cancer Immunology Research. 6(5). 566–577. 23 indexed citations
14.
Orberg, Erik Thiele, Hongni Fan, Ada Tam, et al.. (2016). The myeloid immune signature of enterotoxigenic Bacteroides fragilis-induced murine colon tumorigenesis. Mucosal Immunology. 10(2). 421–433. 157 indexed citations
15.
Fu, Juan, et al.. (2014). Preclinical Evidence That PD1 Blockade Cooperates with Cancer Vaccine TEGVAX to Elicit Regression of Established Tumors. Cancer Research. 74(15). 4042–4052. 106 indexed citations
16.
Vasquez-Dunddel, David, Fan Pan, Qi Zeng, et al.. (2013). STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. Journal of Clinical Investigation. 123(4). 1580–1589. 428 indexed citations
17.
Faraday, Nauder, Sofiyan Saleem, Juan Fu, et al.. (2013). Cathepsin G-Dependent Modulation of Platelet Thrombus Formation In Vivo by Blood Neutrophils. PLoS ONE. 8(8). e71447–e71447. 63 indexed citations
18.
Lu, Qin, B. Douglas Smith, Hua-Ling Tsai, et al.. (2013). Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy. Blood Cancer Journal. 3(9). e145–e145. 19 indexed citations
19.
Davis, Meghan B., et al.. (2011). Intratumoral Administration of TLR4 Agonist Absorbed into a Cellular Vector Improves Antitumor Responses. Clinical Cancer Research. 17(12). 3984–3992. 54 indexed citations
20.
Dang, Eric V., Huang‐Yu Yang, Hong Yu, et al.. (2011). Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1. Cell. 146(5). 772–784. 1261 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026